Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,326,085
  • Shares Outstanding, K 96,478
  • Annual Sales, $ 560,230 K
  • Annual Income, $ -569,180 K
  • EBIT $ -544 M
  • EBITDA $ -521 M
  • 60-Month Beta 0.15
  • Price/Sales 3.73
  • Price/Cash Flow N/A
  • Price/Book 256.70

Options Overview Details

View History
  • Implied Volatility 60.96% (+6.13%)
  • Historical Volatility 171.39%
  • IV Percentile 52%
  • IV Rank 15.59%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 1) 1.29 (5.37%)
  • Put/Call Vol Ratio 42.84
  • Today's Volume 8,418
  • Volume Avg (30-Day) 3,253
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 70,810
  • Open Int (30-Day) 67,272
  • Expected Range 22.78 to 25.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.27
  • Number of Estimates 10
  • High Estimate -0.71
  • Low Estimate -1.76
  • Prior Year -1.39
  • Growth Rate Est. (year over year) +8.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.41 +30.74%
on 12/29/25
36.81 -34.61%
on 12/15/25
-12.16 (-33.56%)
since 12/12/25
3-Month
18.41 +30.74%
on 12/29/25
39.89 -39.66%
on 12/08/25
-7.62 (-24.05%)
since 10/14/25
52-Week
18.41 +30.74%
on 12/29/25
46.50 -48.24%
on 02/06/25
-15.95 (-39.86%)
since 01/14/25

Most Recent Stories

More News
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Ultragenyx Pharmaceutical Inc. (RARE)

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.")...

RARE : 24.07 (-0.17%)
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance  Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated...

RARE : 24.07 (-0.17%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors...

RARE : 24.07 (-0.17%)
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 24.07 (-0.17%)
Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. March E-mini...

C : 112.41 (-3.34%)
RARE : 24.07 (-0.17%)
HL : 23.80 (-2.10%)
SLB : 46.97 (+2.33%)
$IUXX : 25,465.94 (-1.07%)
ZNH26 : 112-135 (-0.04%)
OXY : 44.32 (+2.33%)
ESH26 : 6,991.00 (+0.36%)
FANG : 153.73 (+1.67%)
JBL : 241.34 (+1.25%)
$DOWI : 49,149.63 (-0.09%)
SPY : 690.36 (-0.49%)
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

NOVATO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA)...

RARE : 24.07 (-0.17%)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 112.41 (-3.34%)
RARE : 24.07 (-0.17%)
SLB : 46.97 (+2.33%)
$IUXX : 25,465.94 (-1.07%)
ZNH26 : 112-135 (-0.04%)
OXY : 44.32 (+2.33%)
ESH26 : 6,991.00 (+0.36%)
FANG : 153.73 (+1.67%)
$DOWI : 49,149.63 (-0.09%)
SPY : 690.36 (-0.49%)
DIA : 491.58 (-0.07%)
INSM : 163.46 (-0.16%)
S&P Futures Tread Water Ahead of FOMC Meeting Minutes

March S&P 500 E-Mini futures (ESH26) are trending down -0.02% this morning as investors adopt a cautious stance ahead of the release of the Federal Reserve’s December meeting minutes.

NVDA : 183.14 (-1.44%)
FRES.LN : 3,674.000 (-2.44%)
TSLA : 439.20 (-1.79%)
RARE : 24.07 (-0.17%)
NEM : 114.15 (-0.42%)
NKLR : 6.47 (+13.11%)
FCX : 60.35 (+1.70%)
BHP : 66.02 (+3.17%)
DBRG : 15.36 (+0.07%)
ESH26 : 6,991.00 (+0.36%)
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of...

RARE : 24.07 (-0.17%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 24.07 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 24.97
2nd Resistance Point 24.64
1st Resistance Point 24.36
Last Price 24.07
1st Support Level 23.75
2nd Support Level 23.42
3rd Support Level 23.14

See More

52-Week High 46.50
Fibonacci 61.8% 35.77
Fibonacci 50% 32.46
Fibonacci 38.2% 29.14
Last Price 24.07
52-Week Low 18.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar